• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A short term quality control tool for biodegradable microspheres.一种用于可生物降解微球的短期质量控制工具。
AAPS PharmSciTech. 2014 Jun;15(3):530-41. doi: 10.1208/s12249-013-0052-0. Epub 2014 Feb 12.
2
Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.可植入聚丙交酯乙交酯微球/聚乙烯醇水凝胶复合涂层的体外加速释放试验。
Int J Pharm. 2012 Jan 17;422(1-2):341-8. doi: 10.1016/j.ijpharm.2011.10.020. Epub 2011 Oct 13.
3
A biodegradable polymeric system for peptide-protein delivery assembled with porous microspheres and nanoparticles, using an adsorption/infiltration process.采用吸附/渗透工艺,将多孔微球和纳米颗粒组装成用于肽-蛋白递药的可生物降解聚合物系统。
Int J Nanomedicine. 2013;8:2141-51. doi: 10.2147/IJN.S44482. Epub 2013 Jun 10.
4
Polymer source affects in vitro-in vivo correlation of leuprolide acetate PLGA microspheres.聚合物来源对醋酸亮丙瑞林 PLGA 微球的体外-体内相关性的影响。
Int J Pharm. 2022 Sep 25;625:122032. doi: 10.1016/j.ijpharm.2022.122032. Epub 2022 Jul 22.
5
Interfacial Fast Release Layer in Monodisperse Poly (lactic-co-glycolic acid) Microspheres Accelerates the Drug Release.单分散聚(乳酸-乙醇酸)微球中的界面快速释放层可加速药物释放。
Curr Drug Deliv. 2016;13(5):720-9. doi: 10.2174/1567201813666151130221030.
6
Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.制造变量和原材料对用于 1 个月控释亮丙瑞林的组成等效 PLGA 微球的影响。
Mol Pharm. 2020 May 4;17(5):1502-1515. doi: 10.1021/acs.molpharmaceut.9b01188. Epub 2020 Apr 6.
7
Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.低分子量肝素可吸入大孔微球:体外和体内评价
J Control Release. 2008 Jun 24;128(3):224-32. doi: 10.1016/j.jconrel.2008.03.013. Epub 2008 Mar 21.
8
Validation of a cage implant system for assessing in vivo performance of long-acting release microspheres.用于评估长效释放微球体内性能的笼式植入系统的验证。
Biomaterials. 2016 Dec;109:88-96. doi: 10.1016/j.biomaterials.2016.07.041. Epub 2016 Aug 18.
9
Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.载肽 PLGA 微球的 A 级体外-体内相关性的建立。
J Control Release. 2019 Aug 28;308:1-13. doi: 10.1016/j.jconrel.2019.07.013. Epub 2019 Jul 10.
10
A reproducible accelerated in vitro release testing method for PLGA microspheres.一种用于聚乳酸-羟基乙酸共聚物(PLGA)微球的可重现的加速体外释放测试方法。
Int J Pharm. 2016 Feb 10;498(1-2):274-82. doi: 10.1016/j.ijpharm.2015.12.031. Epub 2015 Dec 15.

引用本文的文献

1
The Effect of Polymer Blends on the In Vitro Release/Degradation and Pharmacokinetics of Moxidectin-Loaded PLGA Microspheres.聚合物共混物对载米多君 PLGA 微球的体外释放/降解和药代动力学的影响。
Int J Mol Sci. 2023 Sep 29;24(19):14729. doi: 10.3390/ijms241914729.
2
Application of a Customised Franz-Type Cell Coupled with HPTLC to Monitor the Timed Release of Bioactive Components in Complex Honey Matrices.定制的Franz型扩散池结合高效薄层层析法用于监测复杂蜂蜜基质中生物活性成分的定时释放
Methods Protoc. 2023 Aug 3;6(4):70. doi: 10.3390/mps6040070.
3
PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery.PLGA/PLA 基长效注射储库微球的临床应用:蛋白/肽给药的生产和特性概述。
Int J Mol Sci. 2021 Aug 18;22(16):8884. doi: 10.3390/ijms22168884.
4
In vitro-in vivo correlation from lactide-co-glycolide polymeric dosage forms.丙交酯-乙交酯共聚物剂型的体外-体内相关性
Prog Biomater. 2014 Dec;3(2-4):131-142. doi: 10.1007/s40204-014-0029-4. Epub 2014 Dec 2.
5
A reproducible accelerated in vitro release testing method for PLGA microspheres.一种用于聚乳酸-羟基乙酸共聚物(PLGA)微球的可重现的加速体外释放测试方法。
Int J Pharm. 2016 Feb 10;498(1-2):274-82. doi: 10.1016/j.ijpharm.2015.12.031. Epub 2015 Dec 15.
6
In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.注射用利培酮聚合物微球的体外-体内相关性
J Control Release. 2015 Nov 28;218:2-12. doi: 10.1016/j.jconrel.2015.09.051. Epub 2015 Sep 28.

本文引用的文献

1
Preparation, Characterization, and In Vivo Evaluation of Olanzapine Poly(D,L-lactide-co-glycolide) Microspheres.奥氮平聚(D,L-丙交酯-共-乙交酯)微球的制备、表征及体内评价
J Pharm (Cairo). 2013;2013:831381. doi: 10.1155/2013/831381. Epub 2013 Aug 12.
2
Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta.采用利培酮微球注射液(长效注射剂)验证 USP 仪器 4 法进行微球体外释放度试验。
Int J Pharm. 2011 Nov 28;420(2):198-205. doi: 10.1016/j.ijpharm.2011.08.035. Epub 2011 Aug 24.
3
Acceleration of in vitro dissolution studies of sustained release dosage form of theophylline and in vitro-in vivo evaluations in terms of correlations.茶碱缓释剂型体外溶出研究的加速以及体外-体内相关性评价。
Eur J Drug Metab Pharmacokinet. 2011 Dec;36(4):243-8. doi: 10.1007/s13318-011-0049-6. Epub 2011 Jul 8.
4
Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer.使用人血清白蛋白作为稳定剂将重组人红细胞生成素稳定并包封于 PLGA 微球中。
Int J Pharm. 2011 Sep 15;416(1):69-76. doi: 10.1016/j.ijpharm.2011.06.008. Epub 2011 Jun 15.
5
Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug.载不稳定抗帕金森前药的聚(乳酸-共-乙醇酸)微球的制备及表征。
Int J Pharm. 2011 May 16;409(1-2):289-96. doi: 10.1016/j.ijpharm.2011.02.036. Epub 2011 Feb 26.
6
PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.载聚乙二醇化肿瘤坏死因子相关凋亡诱导配体(TRAIL)的聚乳酸-乙醇酸共聚物微球,以增强稳定性和抗肿瘤活性。
J Control Release. 2011 Feb 28;150(1):63-9. doi: 10.1016/j.jconrel.2010.10.037. Epub 2010 Nov 6.
7
Preparation of pingyangmycin PLGA microspheres and related in vitro/in vivo studies.平阳霉素 PLGA 微球的制备及相关的体内外研究。
Int J Pharm. 2010 Oct 15;398(1-2):130-6. doi: 10.1016/j.ijpharm.2010.07.045. Epub 2010 Aug 3.
8
Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres.托特罗定 PLGA 微球的制备、表征及药理学评价研究。
Int J Pharm. 2010 Sep 15;397(1-2):44-9. doi: 10.1016/j.ijpharm.2010.06.042. Epub 2010 Jun 30.
9
Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release.含新型强效成骨化合物和新型合成聚合物的可生物降解微球的制备与评价及其缓释
Int J Pharm. 2010 Jun 15;392(1-2):42-50. doi: 10.1016/j.ijpharm.2010.03.020. Epub 2010 Mar 20.
10
Epidural, intrathecal and plasma pharmacokinetic study of epidural ropivacaine in PLGA-microspheres in sheep model.绵羊模型中PLGA微球包裹的罗哌卡因硬膜外给药的硬膜外、鞘内及血浆药代动力学研究
Eur J Pharm Biopharm. 2009 May;72(1):54-61. doi: 10.1016/j.ejpb.2008.11.003. Epub 2008 Nov 25.

一种用于可生物降解微球的短期质量控制工具。

A short term quality control tool for biodegradable microspheres.

作者信息

D'Souza Susan, Faraj Jabar A, Dorati Rossella, DeLuca Patrick P

机构信息

University of Kentucky College of Pharmacy, Lexington, Kentucky, 40536, USA,

出版信息

AAPS PharmSciTech. 2014 Jun;15(3):530-41. doi: 10.1208/s12249-013-0052-0. Epub 2014 Feb 12.

DOI:10.1208/s12249-013-0052-0
PMID:24519488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4037492/
Abstract

Accelerated in vitro release testing methodology has been developed as an indicator of product performance to be used as a discriminatory quality control (QC) technique for the release of clinical and commercial batches of biodegradable microspheres. While product performance of biodegradable microspheres can be verified by in vivo and/or in vitro experiments, such evaluation can be particularly challenging because of slow polymer degradation, resulting in extended study times, labor, and expense. Three batches of Leuprolide poly(lactic-co-glycolic acid) (PLGA) microspheres having varying morphology (process variants having different particle size and specific surface area) were manufactured by the solvent extraction/evaporation technique. Tests involving in vitro release, polymer degradation and hydration of the microspheres were performed on the three batches at 55°C. In vitro peptide release at 55°C was analyzed using a previously derived modification of the Weibull function termed the modified Weibull equation (MWE). Experimental observations and data analysis confirm excellent reproducibility studies within and between batches of the microsphere formulations demonstrating the predictability of the accelerated experiments at 55°C. The accelerated test method was also successfully able to distinguish the in vitro product performance between the three batches having varying morphology (process variants), indicating that it is a suitable QC tool to discriminate product or process variants in clinical or commercial batches of microspheres. Additionally, data analysis utilized the MWE to further quantify the differences obtained from the accelerated in vitro product performance test between process variants, thereby enhancing the discriminatory power of the accelerated methodology at 55°C.

摘要

已开发出加速体外释放测试方法,作为产品性能指标,用作临床和商业批次可生物降解微球放行的鉴别性质量控制(QC)技术。虽然可生物降解微球的产品性能可通过体内和/或体外实验进行验证,但由于聚合物降解缓慢,这种评估可能特别具有挑战性,导致研究时间延长、劳动量大且费用高。通过溶剂萃取/蒸发技术制备了三批形态各异(具有不同粒径和比表面积的工艺变体)的亮丙瑞林聚乳酸-羟基乙酸共聚物(PLGA)微球。在55°C下对这三批微球进行了体外释放、聚合物降解和微球水合测试。使用先前推导的称为修正威布尔方程(MWE)的威布尔函数修正形式分析了55°C下的体外肽释放。实验观察和数据分析证实了微球制剂批次内和批次间出色的重现性研究,证明了55°C加速实验的可预测性。加速测试方法还成功地区分了具有不同形态(工艺变体)的三批微球之间的体外产品性能,表明它是鉴别临床或商业批次微球中产品或工艺变体的合适QC工具。此外,数据分析利用MWE进一步量化了工艺变体之间加速体外产品性能测试获得的差异,从而增强了55°C加速方法的鉴别能力。